Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
JCR Impact Factor (IF) – 2.1
5-Year Impact Factor – 2.2
Scopus CiteScore – 3.4 (CiteScore Tracker 3.7)
Index Copernicus  – 161.11; MNiSW – 70 pts

ISSN 1899–5276 (print)
ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2019, vol. 28, nr 10, October, p. 1377–1383

doi: 10.17219/acem/109759

Publication type: original article

Language: English

Download citation:

  • BIBTEX (JabRef, Mendeley)
  • RIS (Papers, Reference Manager, RefWorks, Zotero)

The effect of the population-based cervical cancer screening program on 5-year survival in cervical cancer patients in Lower Silesia

Dominika Zielecka-Dębska1,2,A,B,C,D,E, Jerzy Błaszczyk3,A,B,D,E, Dawid Błaszczyk4,B,C,E, Jolanta Szelachowska1,2,C,D,E, Krystian Lichoń1,2,A,B,D,E, Adam Maciejczyk1,2,D,E, Rafał Matkowski5,2,A,D,E,F

1 Radiotherapy Department, Lower Silesian Oncology Centre in Wrocław, Poland

2 Department of Oncology, Faculty of Medicine, Wroclaw Medical University, Poland

3 Department of Epidemiology and Lower Silesian Cancer Registry, Lower Silesian Oncology Centre in Wrocław, Poland

4 Lower Silesian Coordinating Center for Preventive Programs, Lower Silesian Oncology Centre in Wrocław, Poland

5 Breast Unit, Lower Silesian Oncology Centre in Wrocław, Poland

Abstract

Background. Poland is considered among the European countries with an average incidence of cervical cancer (CC; about 3,000–3,500/year) and at the same time with high mortality (5-year survival rate – 55.2%). For this reason, in 2006 Poland introduced a Population-Based Cervical Cancer Prevention and Early Detection Program addressed to women aged 25–59 years, in which a cytological test is carried out every 3 years.
Objectives. The aim of the study was to assess the changes in the curability of CC patients brought by the introduction of the Screening Program in the Lower Silesian voivodeship and to identify the subpopulation of women for whom activities aimed at increasing adherence rates must be intensified.
Material and Methods. The 5-year relative survival in 3,586 CC patients from 2000–2010 registered in the Lower Silesian Cancer Registry was analyzed.
Results. In the Lower Silesian voivodeship, a 55.1% 5-year survival rate was recorded in 2000–2004 and 70.5% in 2010. The highest increase in 5-year relative survival rates was found in rural communities (from 53.1% in 2000–2004 to 77.7% in 2010) and in Wrocław (56.8% and 74.2%, respectively). In the study group, the number of patients with invasive CC (C53) detected in the local stage of the disease increased systematically from 61.5% in 2000–2004 to 74.3% in 2010.
Conclusion. The introduction of the population-based screening program improved the curability rate in CC patients in the Lower Silesian voivodeship. In order to maintain the recent positive trends, further education should be continued, and activities aimed at increasing adherence to screening tests should be intensified, especially in urban-rural communities.

Key words

cervical cancer, screening tests, cancer epidemiology

References (22)

  1. Barnaś E, Borowiec-Domka E, Kądziołka J, Grzegorczyk J. Factors affecting the response-rate to cytology examinations of women in the Subcarpathian region, National Programme of Cervical Cancer Prophylaxis [in Polish]. Probl Hig Epidemiol. 2008;89(4):482–486.
  2. World Health Organization, Department of Information, Evidence and Research. Mortality database. http://www-dep.iarc.fr/WHOdb/table2.asp of subordinate document. Accessed March 31, 2019.
  3. Nowicki A, Borowa I, Maruszak M. Women health behaviours regarding prevention and early detection of precancerous lesions and cervical carcinoma [in Polish]. Ginekol Pol. 2008;79(12):840–849.
  4. Denny L, Kuhn L, De Souza M, Pollack AE, Dupree W, Wright TC Jr. Screen-and-treat approaches for cervical cancer prevention in low-resource settings: A randomized controlled trial. JAMA. 2005;294(17):2173–2181.
  5. Goldie SJ, Gaffikin L, Goldhaber-Fiebert JD, et al; Alliance for Cervical Cancer Prevention Cost Working Group. Cost-effectiveness of cervical-cancer screening in five developing countries. N Engl J Med. 2005;353(20):2158–2168.
  6. Mariańczyk K, Steuden S. Expectations and intentions of health behaviours as factors determinating performance of preventive Pap smear among women aged over 45 [in Polish]. Psycho­onkologia. 2011;2:55–64.
  7. Nowakowski A, Wojciechowska U, Wieszczy P, Cybulski M, Kamiński MF, Didkowska J. Trends in cervical cancer incidence and mortality in Poland: Is there an impact of the introduction of the organised screening? Eur J Epidemiol. 2017;32(6):529–532.
  8. Gustafsson L, Ponten J, Zack M, Adami H-O. International incidence rates of invasive cervical cancer after introduction of cytological screening. Cancer Causes Control. 1997;8(5):755–763.
  9. Spaczyński M, Karowicz-Bilinska A, Kędzia W, et al. Costs of Population Cervical Cancer Screening Program in Poland between 2007–2009 [in Polish]. Ginekol Pol. 2010;81(10):750–756.
  10. Anttila A, Pukkala E, Söderman B, Kallio M, Nieminen P, Hakama M. Effect of organised screening on cervical cancer incidence and mortality in Finland, 1963–1995: Recent increase in cervical cancer incidence. Int J Cancer. 1999;83(1):59–65.
  11. Zielecka D, Lichoń K, Maciejczyk A, Błaszczyk J, Błaszczyk D, Matkow­ski R. Wpływ cytologicznych badań przesiewowych na zachorowania na raka szyjki macicy w województwie dolnośląskim w latach 2005–2014. Postepy Hig Med Dosw. 2018;72:13–20.
  12. Słopiecka A, Wiraszka G. Women’s attitudes towards reproductive system disease prevention. Eur J Clin Invest. 2013;1:50–60.
  13. Wojciechowska U, Didkowska J. Zachorowania i zgony na nowotwory złośliwe w Polsce. In: Krajowy Rejestr Nowotworów, Centrum Onkologii – Instytut im. Marii Skłodowskiej-Curie. http://onkologia.org.pl/raporty/of subordinate document. Accessed March 27, 2019.
  14. Sergio P. 25th Annual Report on the Results of Treatment of Gynecological Cancer. London, UK: Elsevier Health Sciences; 2003.
  15. Spaczyński M, Nowak-Markwitz E, Witold K. Cervical cancer screening in Poland and worldwide [in Polish]. Ginekol Pol. 2007;78(5):354–360.
  16. Moyer VA; U.S. Preventive Services Task Force. Screening for Cervical Cancer: U.S. Preventive Services Task Force Recommendation Statement. Ann Intern Med. 2012;156(12):880–891.
  17. Dillner J, Rebolj M, Birembaut P, et al. Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: Joint European cohort study. BMJ. 2008;337:1756–1833.
  18. Karczmarek-Borowska B, Grądalska-Lampart M. Cervical cancer incidence and mortality rates including the screening program results in the Podkarpackie Region between 1999–2010 [in Polish]. Ginekol Pol. 2013;84(11):930–937.
  19. Tuchowska P, Worach-Kardas H, Marcinkowski JT. The most frequent malignant tumors in Poland: The main risk factors and opportunities to optimize preventive measures [in Polish]. Probl Hig Epidemiol. 2013;94(2):166–171.
  20. Wrześniewska M, Adamczyk-Gruszka O, Gruszka J, Bąk B. Diagnostic and therapeutic possibilities in the prophylaxis of cervical cancer [in Polish]. Stud Med. 2013;29(1):109–116.
  21. Sant M, Chirlaque Lopez MD, Agresti R, et al; EUROCARE-5 Working Group. Survival of women with cancers of breast and genital organs in Europe 1999–2007: Results of the EUROCARE-5 study. Eur J Cancer. 2015;51(15):2191–2205.
  22. Berrino F, De Angelis R, Sant M, et al; EUROCARE-4 Working Group. Survival for eight major cancers and all cancers combined for European adults diagnosed in 1995–99: Results of the EUROCARE-4 study. Lancet Oncol. 2007;8(9):773–783.